Autopsy report · NCT03430466

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

“Recruiting was not possible”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 1 year 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Kyoto Breast Cancer Research Network

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Durvalmab&Tremelimumab&Fulvestrant

Participants

1

Sites

1

Countries

Japan

Trials that died the same way

• Early Administration of the Lutein/Zeaxanthin in Premature Newborns
  “Recruitment was not possible” (89% match in meaning)
• Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer
  “insufficient recruiting” (80% match in meaning)
• Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?
  “could not recruit” (79% match in meaning)
• Fluorescence Targeted Pelvic Lymph Node Mapping
  “Not able to recruit” (79% match in meaning)
• Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children
  “Unable to adequatly recruit” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.